Investor Relations

Company Information

MiNK Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class invariant natural killer T (iNKT) cell therapies to transform the lives of patients with cancer.
Press Releases
Jan 11, 2023
NEW YORK , Jan. 11, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. , a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated
Nov 17, 2022
NEW YORK , Nov. 17, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. ,  a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated
Corporate Presentation

SEC Filings

Form Description Filing date View
SC 13G

A statement of beneficial ownership of common stock by certain persons

View HTML
S-1/A

Amended Registration statement for face-amount certificate companies

View HTML
DRS/A

Amendment to a previously filed DRS

View HTML
DRS/A

Amendment to a previously filed DRS

View HTML

Data provided by Kaleidoscope.

Events and Presentations